UNSPSC 51352211: Hexestrol diphosphate sodium

This classification denotes a non-steroidal estrogen with the molecular formula C18H20O8P2.4Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VK60X9E36E, chemically known as phenol, 4,4'-((1r,2s)-1,2-diethyl-1,2-ethanediyl)bis-, bis(dihydrogen phosphate), tetrasodium salt, rel-, but more generally known as hexestrol diphosphate sodium, which bears US NIH Compound Identifier 3064060.

European Medicines Agency schedules hexestrol diphosphate sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08036MIG. Most nations, for tariff purposes, schedule hexestrol diphosphate sodium under HS 29072900. SMILES: CC[C@H](C1CCC(CC1)OP(=O)([O-])[O-])[C@@H](CC)C2CCC(CC2)OP(=O)([O-])[O-].[NA+].[NA+].[NA+].[NA+].

UNSPSC 51352211 Hexestrol diphosphate sodium is a Commodity code representing specialty pharmaceutical ingredients and active pharmaceutical compounds procured through state and local cooperative purchasing vehicles. State and local governments buy under this code primarily through multistate pharmaceutical procurement alliances that aggregate demand across participating agencies, school districts, and health facilities. The scope encompasses generic and brand-name active ingredients, intermediates, and finished pharmaceutical products supplied through authorized pharmaceutical wholesalers under negotiated master agreements. Issuing bodies include state departments of administration and health, cooperative purchasing organizations like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), and participating state and local health systems, correctional facilities, and social services agencies across member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two of the three. The RFP requires cGMP and Drug Supply Chain Security Act (DSCSA) certification, commercial general liability coverage of $5 million per occurrence, network security and privacy liability of $2 million, professional liability of $2 million, pricing submission in multiple formats (flat price, net price NF30/NF60/NF90, or WAC-minus), and compliance with a 3 percent administrative fee structure. The contract term runs two years for new responders with optional MMCAP extensions, through June 30, 2028 for incumbent amendments. Evaluation weighs price competitiveness at 75 percent, fixed pricing at 10 percent, compliance with administrative fee data format at 5 percent, EDI capability at 5 percent, and agreement to the 3 percent administrative fee at 5 percent. Minnesota and Oregon participate in this cooperative vehicle; the RFP does not disclose specific set-aside designations or budget ranges.